It is a fully human recombinant monoclonal antibody (MAB).
Mechanism of action:
It gets bind to human TNF-α receptor site thus stops endogenous TNF- α activity by preventing its interaction with p55 and p75 cell surface receptors.
It decreases symptoms of Rheumatoid arthritis and stops erosion of the (bone) structure.
It is used in Rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis. (As increased TNF in the synovial fluid cause pain and joint destruction in Rheumatoid arthritis).
It is used subcutaneously and its half life is 10-20 days.
Dose and Administration:
Its usual dose is 40 mg every other week. It is used Subcutaneously only.
It may cause headache, nausea, rashes and reactions at the site of injection.